Evidence map›Paper›PMID 38998955›Full record

ReviewMolecules (Basel, Switzerland)2024

The Chromenopyridine Scaffold: A Privileged Platform in Drug Design.

Fábio Pedroso de Lima, Marta Costa, Ana Sousa, Maria Fernanda Proença

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fábio Pedroso de LimaChemistry Centre, School of Sciences, University of Minho, Gualtar Campus, 4715-303 Braga, Portugal.ORCID 0000-0003-4368-6228
Marta CostaLife and Health Sciences Research Institute (ICVS), University of Minho, Gualtar Campus, 4710-057 Braga, Portugal.ORCID 0000-0002-4287-0659
Ana SousaChemistry Centre, School of Sciences, University of Minho, Gualtar Campus, 4715-303 Braga, Portugal.
Maria Fernanda ProençaChemistry Centre, School of Sciences, University of Minho, Gualtar Campus, 4715-303 Braga, Portugal.ORCID 0000-0002-5274-1949

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The chromenopyridine scaffold represents an important class of heterocyclic compounds exhibiting a broad spectrum of biological properties. This review describes novel and efficient procedures for the synthesis of this scaffold. Herein, several methods were detailed and grouped according to their starting material (e.g., salicylaldehydes, chromones, chromanones and coumarins) and respective biological activity, when reported. This review highlights the potential of the reported synthetic strategies for preparing chromenopyridine derivatives with promising biological activity, paving the way for further developments in drug discovery.

Indexed as

Drug DesignPyridinesChromonesCoumarinsHumansMolecular StructureStructure-Activity RelationshipChromonesCoumarinsPyridinesbiological activitychromenechromenopyridinepyridinesynthesis

Identifiers

PMID38998955
PMCPMC11243271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.